5 of Canada’s biggest market winners and losers in 2013
John Shmuel and David Pett | January 1, 2014 7:00 AM ET
We take a look at five of the best- and worst-performing stocks in the Toronto Stock Exchange’s S&P/TSX 60 index during 2013.
BEST
By John Shmuel
Valeant Pharmaceuticals International Inc. (VRX/TSX)
Annual return: 110.01%
Canada’s largest publicly-traded drug company was also the biggest winner on the S&P/TSX 60 Index in 2013. Valeant Pharmaceuticals International’s stock price more than doubled for the year as investors rewarded the company for its active and profitable acquisition streak. Valeant’s most recent deal, on Dec. 16, was an offer to buy U.S.-based medical-device company Solta for a 40% premium. RBC analyst Douglas Miehm gave the deal a big thumbs up, saying it showed Valeant’s ongoing efforts to expand its business. He also hiked his price target for Valeant to $120 from $117 following the announcement. Adding further allure for investors heading into 2014, Valeant’s management in October said they continue to hunt for profitable acquisitions and that Valeant would even be open to a “merger of equals.” Read more of this post